Assetmark Inc. Acquires 24,425 Shares of Novo Nordisk A/S $NVO

Assetmark Inc. increased its holdings in Novo Nordisk A/S (NYSE:NVO) by 11.2% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 241,924 shares of the company’s stock after buying an additional 24,425 shares during the period. Assetmark Inc.’s holdings in Novo Nordisk A/S were worth $13,424,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also added to or reduced their stakes in NVO. 1776 Wealth LLC bought a new position in shares of Novo Nordisk A/S during the third quarter valued at $473,000. ICW Investment Advisors LLC raised its position in Novo Nordisk A/S by 5.6% during the 3rd quarter. ICW Investment Advisors LLC now owns 44,575 shares of the company’s stock worth $2,473,000 after purchasing an additional 2,349 shares during the last quarter. Savvy Advisors Inc. lifted its holdings in Novo Nordisk A/S by 83.0% during the 3rd quarter. Savvy Advisors Inc. now owns 48,824 shares of the company’s stock worth $2,709,000 after buying an additional 22,138 shares during the period. GK Wealth Management LLC grew its position in shares of Novo Nordisk A/S by 26.4% in the 3rd quarter. GK Wealth Management LLC now owns 6,086 shares of the company’s stock valued at $338,000 after buying an additional 1,270 shares during the last quarter. Finally, Caprock Group LLC acquired a new stake in shares of Novo Nordisk A/S in the third quarter valued at about $2,784,000. Institutional investors and hedge funds own 11.54% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages recently commented on NVO. CICC Research began coverage on Novo Nordisk A/S in a report on Friday, January 9th. They issued an “outperform” rating and a $73.50 target price on the stock. HSBC reaffirmed a “hold” rating and issued a $54.00 price objective on shares of Novo Nordisk A/S in a research note on Wednesday, December 10th. Weiss Ratings raised shares of Novo Nordisk A/S from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Thursday, February 5th. BMO Capital Markets reaffirmed a “market perform” rating on shares of Novo Nordisk A/S in a research report on Thursday, February 5th. Finally, Argus reiterated a “hold” rating on shares of Novo Nordisk A/S in a report on Monday, December 8th. Seven analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Novo Nordisk A/S currently has an average rating of “Hold” and an average target price of $56.07.

Novo Nordisk A/S News Roundup

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Berenberg maintained its Buy rating on Novo Nordisk, reinforcing investor confidence in the company’s growth outlook and valuation support from a respected European bank. Berenberg Bank Sticks to Their Buy Rating for Novo Nordisk (NVO)
• Positive Sentiment: IQVIA data show Wegovy oral-pill prescriptions hitting ~38,220 in week five post-launch, signaling strong early uptake for the new oral formulation and supporting near-term revenue momentum. Novo’s Wegovy pill tracks over 38,000 prescriptions in fifth week
• Positive Sentiment: Company update: Novo completed a Phase 3 study of oral semaglutide in youth diabetes care — a potential label expansion that could broaden the drug’s addressable market if approved. Novo Nordisk Advances Oral Semaglutide Into Youth Diabetes Care
• Positive Sentiment: Legal/market protection: U.S. officials may act against Hims after its attempted sale of a compounded Wegovy copy, which could help defend Novo’s IP and commercial position. US could take action including fines against Hims after brief Wegovy copy launch
• Positive Sentiment: Product strategy: Novo plans to introduce Wegovy in vial presentations (and other device formats), a move to improve access, pricing flexibility and supply resiliency amid competition. Novo Nordisk plans Wegovy vials amid obesity-drug competition
• Positive Sentiment: Usage trend: A study finds many Wegovy pill users are new to GLP‑1s, suggesting the product is bringing first‑time patients into the class and expanding market demand. Many users of Novo Nordisk Wegovy pill new to GLP-1s – study
• Neutral Sentiment: Company expansion: Coverage on Novo’s broader global healthcare initiatives highlights long‑term growth avenues but is less likely to move near‑term sentiment. How Is Novo Nordisk (NYSE:NVO) Expanding Its Global Healthcare Reach?
• Neutral Sentiment: Industry context: A CNBC piece on pharma’s “reset” around pricing and pipelines frames regulatory and pricing headwinds that apply across the sector. Prices, pipelines and patent cliffs: Inside pharma’s big reset
• Neutral Sentiment: Competitive landscape: Analysis comparing Eli Lilly and Novo Nordisk underscores intense competition in a rapidly growing weight‑loss market; investors should watch share trends and margin pressure. Eli Lilly vs Novo Nordisk in the Weight Loss Drug Market
• Negative Sentiment: Regulatory/legal risk: Coverage about FDA warnings and potential lawsuits tied to Wegovy highlights an ongoing downside risk to valuation if safety signals or litigation escalate. FDA Wegovy Warning And Lawsuits Test Novo Nordisk Valuation Story

Novo Nordisk A/S Stock Up 1.4%

NVO stock opened at $49.59 on Monday. The stock’s 50 day simple moving average is $53.74 and its 200 day simple moving average is $53.24. The company has a market cap of $221.43 billion, a P/E ratio of 14.29 and a beta of 0.67. The company has a debt-to-equity ratio of 0.61, a quick ratio of 0.57 and a current ratio of 0.80. Novo Nordisk A/S has a fifty-two week low of $43.08 and a fifty-two week high of $93.80.

Novo Nordisk A/S (NYSE:NVO) last released its quarterly earnings data on Tuesday, February 3rd. The company reported $1.01 EPS for the quarter, beating the consensus estimate of $0.90 by $0.11. Novo Nordisk A/S had a return on equity of 68.91% and a net margin of 33.03%.The firm had revenue of $12.43 billion during the quarter, compared to the consensus estimate of $11.97 billion. On average, research analysts expect that Novo Nordisk A/S will post 3.84 earnings per share for the current fiscal year.

Novo Nordisk A/S Announces Dividend

The firm also recently disclosed a dividend, which will be paid on Wednesday, April 8th. Shareholders of record on Monday, March 30th will be paid a $1.2751 dividend. This represents a dividend yield of 541.0%. The ex-dividend date of this dividend is Monday, March 30th. Novo Nordisk A/S’s dividend payout ratio (DPR) is 23.63%.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.